Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec has received EUR4m milestone payment as a part of research alliance with Boehringer Ingelheim.
Subscribe to our email newsletter
The transition of a respiratory program into pre-clinical development triggered the payment.
Evotec chief operating officer Mario Polywka said the present payment is the sixteenth milestone achieved as part of the company’s alliance with Boehringer Ingelheim and represents an important transition of the program into pre-clinical development.
"The alliance continues to achieve significant scientific and commercial success, reflecting the truly collaborative efforts of teams from Evotec and Boehringer Ingelheim," Polywka added.
In 2004, Evotec entered into a multi-target drug discovery alliance with Boehringer to identify and develop pre-clinical development candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases.
The collaboration was extended for an additional four years and the scope expanded to include oncology targets in 2009.